Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 Chin Med J Engl 134 783-791

[3] Siegel RL(2022)Non-small cell lung cancer in China Cancer Commun Lond 42 937-970

[4] Cao W(2014)Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system Cancer 23 3781-3792

[5] Chen HD(2021)Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC Nat Rev Clin Oncol 18 625-644

[6] Yu YW(2022)First-line immunotherapy for non-small-cell lung cancer J Clin Oncol 40 586-597

[7] Li N(2021)Immunotherapy for non-small cell lung cancer NSCLC; as a stand-alone and in combination therapy Crit Rev Oncol Hematol 164 651-663

[8] Chen WQ(2022)Toripalimab: the first domestic anti-tumor PD-1 antibody in China Front Immunol 12 1-9

[9] Chen P(2023)Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial choice-01 J Clin Oncol 41 601-609

[10] Liu Y(2022)The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer Front Pharmacol 13 153-162

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 Chin Med J Engl 134 783-791

[3] Siegel RL(2022)Non-small cell lung cancer in China Cancer Commun Lond 42 937-970

[4] Cao W(2014)Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system Cancer 23 3781-3792

[5] Chen HD(2021)Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC Nat Rev Clin Oncol 18 625-644

[6] Yu YW(2022)First-line immunotherapy for non-small-cell lung cancer J Clin Oncol 40 586-597

[7] Li N(2021)Immunotherapy for non-small cell lung cancer NSCLC; as a stand-alone and in combination therapy Crit Rev Oncol Hematol 164 651-663

[8] Chen WQ(2022)Toripalimab: the first domestic anti-tumor PD-1 antibody in China Front Immunol 12 1-9

[9] Chen P(2023)Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial choice-01 J Clin Oncol 41 601-609

[10] Liu Y(2022)The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer Front Pharmacol 13 153-162